National Pharmaceutical Council disputes findings by ICER on drug price increases
It argued the ICER study did not consider the full range of clinical data on the drugs it assesses, and that its analyses lack context.
By Scott Wooldridge|November 30, 2021 at 09:39 AM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
A pharmaceutical industry group is pushing back against a recent report that said some drug price increases were not supported by clinical improvement.
The Nov. 16 report by the Institute for Clinical and Economic Review (ICER) said that among the top 10 drugs with price increases in 2020 that had substantial effects on US spending, seven of 10 drugs did not have new evidence of a new clinical benefit. The report focused on Humira, a rheumatoid arthritis drug—which, by itself, accounted for $1.4 billion of the $1.67 billion in additional drug spending.
Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.
Your access to unlimited BenefitsPRO.com content isn’t changing. Once you are an ALM digital member, you’ll receive:
Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
This conversation starter guide for better benefits will walk you through six simple ways to start a productive conversation with your clients that will add value and position you as their broker of choice. Download now to stay ahead in 2022.
There are five different approaches and consulting types when it comes to working with employers on benefits. Identify which type you fall into and learn fresh ideas from the other approaches in this guide.
It’s no secret that health benefits have struggled to keep up with workforce expectations during the Great Resignation. Remaining competitive means employers must streamline their health benefits, put employees first and deliver on brand values. Download this guide to help your clients gain an edge in 2022 with their health benefits.